UNSPSC 51142531: Mazaticol

This classification denotes an anticholinergic agent with the molecular formula C20H25NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I6X824OGWZ, chemically known as 6,6,9-trimethyl-9-azabicyclo(3.3.1)non-3beta-yl di-2-thienylglycolate but generally known as mazaticol, which bears US NIH Compound Identifier 68667. European Medicines Agency schedules Mazaticol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08655MIG.

UNSPSC 51142531 Mazaticol, a Commodity code, encompasses pharmaceutical products and related systems that state and local health agencies procure for community health programs, emergency response, and multi-state cooperative purchasing arrangements. Recent solicitations show state and local governments buying naloxone units and safe drug deactivation systems for public health initiatives, generic multi-source pharmaceuticals distributed through state cooperative purchasing alliances, and direct-to-manufacturer prescription fulfillment capabilities for health benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP) serving state and local government facilities across multiple jurisdictions. The work ranges from annual procurement of specific naloxone and drug deactivation system units with quarterly delivery schedules to establishment of master supply agreements for generic pharmaceuticals through authorized wholesalers, to exploratory information gathering on direct-to-manufacturer contracting models.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with multi-state reach through cooperative purchasing vehicles. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) requesting vendor information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with pricing evaluation weighted heavily on competitiveness (75 percent), effective July 1, 2026, for a two-year initial term. Vendors responding to these opportunities must comply with cGMP and DSCSA certifications, maintain specified insurance coverages, and accept performance penalties for compliance failures.